Keywords: cti, licenses, new, form, paclitaxel, cell, therapeutics
CTI Licenses New Form Of Paclitaxel
Article | 22 July 1998
Cell Therapeutics Inc has licensed the rights to polyglutamic acidpaclitaxel (PG-TXL), a water-soluble form of Bristol-Myers Squibb's best-selling anticancer drug ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Daiichi Sankyo files for Japanese approval of Prasugrel
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
